Safety and Tolerability of PCSK9 Inhibitors: Current Insights

Safety and Tolerability of PCSK9 Inhibitors: Current Insights

Constantine E Kosmas,1 Andreas Skavdis,2 Andreas Sourlas,3 Evangelia J Papakonstantinou,4 Edilberto Peña Genao,5 Rogers Echavarria Uceta,5 Eliscer Guzman1 1Division of Cardiology, Department of Medicine, Montefiore Medical Center, Bronx, NY, USA; 2School of Medicine, University of Athens,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E
Format: article
Langue:EN
Publié: Dove Medical Press 2020
Sujets:
hypercholesterolemia
cardiovascular disease
cvd
pcsk9 inhibitors
safety
tolerability.
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/817a135acf6143918c3328e778e3ad40
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/817a135acf6143918c3328e778e3ad40

Documents similaires